|
[1]
|
Mizushima, T., Ohno, Y., Nakajima, K., Kai, Y., Iijima, H., Sekimoto, M., Nishida, T., et al. (2010) Malignancy in Crohn’s Disease: Incidence and Clinical Characteristics in Japan. Digestion, 81, 265-270.
http://dx.doi.org/10.1159/000273784
|
|
|
[2]
|
Song, Y., Zheng, P., Xiao, J. and Lu, Z. (2014) Efficacy and Safety of Adalimumab for the Crohn’s disease: A Systematic Review and Meta-Analysis of Published Randomized Placebo-Controlled Trials. European Journal of Clinical Pharmacology, 70, 907-914.
http://dx.doi.org/10.1007/s00228-014-1702-1
|
|
|
[3]
|
Mendes, D., Alves, C. and Batel-Marques, F. (2014) Safety Profiles of Adalimumab, Etanercept and Infliximab: A Pharmacovigilance Study Using a Measure of Disproportionality in a Database of Spontaneously Reported Adverse Events. Journal of Clinical Pharmacy and Therapeutics, 39, 307-313.
http://dx.doi.org/10.1111/jcpt.12148
|
|
|
[4]
|
Estlein, D., Ohana, G., Weil, R., Rath-Wolfson, L. and Wolloch, Y. (2001) Early Cancer in Gastric Crohn’s Disease. IMAJ, 3, 379-380.
|
|
|
[5]
|
Bernstein, C., Blanchard, J., Kliewer, E. and Wajda, A. (2001) Cancer Risk in Patients with Inflammatory Bowel Disease. Cancer, 91, 854-862.
http://dx.doi.org/10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z
|
|
|
[6]
|
Hemminki, K., Li, X., Sundquist, J. and Sundquist, K. (2009) Cancer Risks in Crohn Disease Patients. Annals of Oncology, 20, 574-580.
http://dx.doi.org/10.1093/annonc/mdn595
|
|
|
[7]
|
Hudesman, D., Lichtiger, S. and Sands, B. (2013) Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease: Review of the Literature. Inflammatory Bowel Diseases, 19, 644-649.
http://dx.doi.org/10.1097/MIB.0b013e318280ebbd
|
|
|
[8]
|
Persson, P.G., Karlén, P., Bernell, O., Leijonmarck, C.E., Brostrom, O., Ahlbom, A. and Hellers, G. (1994) Crohn’s Disease and Cancer: A Population-Based Cohort Study. Gastroenterology, 107, 1675-1679.
|
|
|
[9]
|
Andersen, N. and Jess, T. (2013) Has the Risk of Colorectal Cancer in Inflammatory Bowel Disease Decreased? World Journal of Gastroenterology, 19, 7561-7568.
http://dx.doi.org/10.3748/wjg.v19.i43.7561
|
|
|
[10]
|
Lutgens, M.W.M.D., Oijen, M.G.H., van der Heijden, G.J.M.G., Vleggaar, F.P., Siersema, P.D. and Oldenburg, B. (2013) Declining Risk of Colorectal Cancer in Inflammatory Bowel Disease: An Updated Meta-Analysis of Population-Based Cohort Studies. Inflammatory Bowel Diseases, 19, 789-799.
http://dx.doi.org/10.1097/MIB.0b013e31828029c0
|
|
|
[11]
|
Ikeuchi, H., Kusunoki, M., Yamamura, T. and Nishigami, T. (2002) Crohn’s Disease Associated with Gastric Cancer. Journal of Gastroenterology, 37, 47-49.
http://dx.doi.org/10.1007/s535-002-8132-6
|
|
|
[12]
|
Nam, J.H., Choi, J., Cho, S., Kim, C.G., Jun, J.K., Choi, K.S., et al. (2012) Association of the Interval between Endoscopies with Gastric Cancer Stage at Diagnosis in a Region of High Prevalence. Cancer, 118, 4953-4960.
http://dx.doi.org/10.1002/cncr.27495
|
|
|
[13]
|
Andersen, N.N., Pasternak, B., Basit, S., Andersson, M., Svanstrom, H., Caspersen, S., et al. (2014) Association between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients with Inflammatory Bowel Disease. JAMA, 311, 2406-2413.
http://dx.doi.org/10.1001/jama.2014.5613
|
|